Edmond de Rothschild Corporate Finance advises LFPI on the sale of its Accolab laboratories to Cerba Healthcare

News - 10/2/2018

LFPI Gestion, a leading French small- and mid-cap private equity player has sold its Accolab laboratories to the Cerba Healthcare group. Following on the sale of EA Pharma, CCA International and Eminence, this is the fourth sale by LFPI in the past months.

Accolab was acquired in March 2015 when it had eight medical biology laboratories. It now has 28 and offers a complete range of medical diagnostics services combining medical biology and anatomo-cytopathology. With the assistance of LFPI, Accolab carried out 12 acquisitions in just over three years to consolidate its position in Aquitaine and Rhône-Alpes and grow its presence in the Paris region and Normandy. Led by Alain Dalléac, Accolab has also established a significant position in the anatomo-cytopathology field in France.

The dynamic acquisition strategy is built on an attractive model for medical professionals who want to join the project by enabling them to reinvest a share of their disposal income in the lead holding company.

Development has continued in 2018 with new specialities like a fertility diagnostics institute at the Trocadero site in Paris and the creation of latest-generation anatomo-cytopathology technical facilities in Le Havre. Accolab will now continue to grow within Cerba Healthcare, an international medical biology group specialised in routine and speciality biology, clinical trials and veterinary biology. It employs over 6,000 people of which over 560 biologists and anatomo-cytopathologists, primarily in Europe.

Advice to sellers in operation

 LFPI advisor

Edmond de Rothschild Corporate Finance:

M&A advisory: Arnaud Petit (Associate Director), Aurélien Bouvier (Vice President), Victor Auguin-Rougier (Analyst)

Financing advisory: Gregory Fradelizi (Associate Director)